Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525934 | 0.83 | CHRM2 (0.32) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL35210602 | 0.79 | NR1H2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL4474052 | 0.79 | PIK3CD (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL875468 | 0.78 | HSD17B10 (0.34) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24337574 | 0.78 | NR1H2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL29459509 | 0.78 | NR1H2 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL874864 | 0.76 | NR1H2 (0.32) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2119467 | 0.76 | NR1H2 (0.32) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL874863 | 0.76 | NR1H2 (0.32) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL25165408 | 0.76 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | CHRM2 3674/4885CHRM1 2219/4885CHRM3 3265/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 3673/4885CHRM1 2349/4885CHRM3 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.